X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Otsuka strengthens its pipeline in the area of psychiatric and neurological disorders by including, MSP-1014 (psilocybin), a new class of agonists that activate the serotonin 5-HT2A receptor.
Lead Product(s): Psilocybine
Therapeutic Area: Neurology Product Name: MSP-1014
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Otsuka Pharmaceutical
Deal Size: $59.2 million Upfront Cash: $59.2 million
Deal Type: Acquisition September 01, 2023
Details:
MSP-1014 is a differentiated psilocybin-based compound from Mindset’s Family 1 of novel, patent-pending psychedelic compounds. MSP-1014 was the first compound identified by the Company to progress towards human clinical trials.
Lead Product(s): MSP-1014
Therapeutic Area: Neurology Product Name: MSP-1014
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2023
Details:
MSP-1014 is a differentiated psilocybin-based compound from Mindset’s Family 1 of novel, patent-pending psychedelic compounds. MSP-1014 was the first compound identified by the Company to progress towards human clinical trials.
Lead Product(s): Psilocybine
Therapeutic Area: Neurology Product Name: MSP-1014
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 20, 2023
Details:
Under the sales agreement, PharmAla will be the exclusive global reseller of Mindset’s cGMP (i.e. pharmaceutical grade) psilocybin to appropriately licensed clinical researchers.
Lead Product(s): Psilocybine
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: PharmAla Biotech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 16, 2022
Details:
MSP-1014 was also evaluated in a drug discrimination assay in which rats were trained to discriminate a psilocybin cue from saline. MSP-1014 displayed complete generalization to the psilocybin cue with a similar ED50 and duration of action (~4 hr) at equimolar doses.
Lead Product(s): MSP-1014
Therapeutic Area: Neurology Product Name: MSP-1014
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2022
Details:
MSP-1014 (psilocin prodrug), a second-generation psilocybin-like drug, demonstrated an improved efficacy, with reduced potential side effects and faster onset of action, and similar duration of effect compared to the first-generation drug candidate psilocybin.
Lead Product(s): Psilocin Prodrug
Therapeutic Area: Neurology Product Name: MSP-1014
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2022
Details:
Under the terms of the Agreement, Cybin will license intellectual property related to preclinical compounds within Mindset’s “Family 1” portfolio, excluding MSP-1014 (psilocybin), Mindset’s lead psychedelic drug candidate.
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: MSP-1014
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cybin
Deal Size: $9.5 million Upfront Cash: $0.5 million
Deal Type: Licensing Agreement September 27, 2022
Details:
In preclinical studies, MSP-1014, demonstrated an improved efficacy and safety profiles, with reduced potential side effects and faster onset of action, and similar duration of effect compared to the first-generation drug candidate psilocybin.
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: MSP-1014
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2022
Details:
Mindset’s scientists designed and developed three new, chemically distinct, small molecule non-tryptamine scaffolds, Families 6, 7 and 8. Mindset has filed provisional patent applications on these families, with favorable FTO searches.
Lead Product(s): Non-tryptamine Psychedelic Derivatives
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2022
Details:
High-potency, short-acting, psilocybin-like novel analogues of psilocybin that exhibit a range of pharmacokinetic and pharmacodynamic improvements in pre-clinical studies for the treatment of CNS disorders.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Otsuka Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 06, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
